Recent

% | $
Quotes you view appear here for quick access.

Amarantus Bioscience Holdings, Inc Message Board

  • joelord57@ymail.com joelord57 Mar 18, 2013 12:11 PM Flag

    March 18, 2013 Amarantus BioScience Appoints Mark Benedyk, Ph.D., to Board of Directors

    SUNNYVALE, Calif.-- Amarantus BioScience, Inc. (OTCQB: AMBS), a biotechnology
    company discovering and developing treatments and diagnostics for diseases associated
    with neurodegeneration and apoptosis centered around its patented therapeutic protein
    Mesencephalic Astrocyte Neurotrophic Factor (MANF), has appointed Mark Benedyk,
    Ph.D., to its Board of Directors. Dr. Benedyk has over 18 years of experience as a senior
    business development executive and consultant to life science companies, and has served
    as a Corporate Advisor to Amarantus since 2011. With the addition of Dr. Benedyk, the
    Amarantus board has four members, two of whom are considered independent directors,
    including Dr. Benedyk.
    “I am excited to join the Amarantus board at such an important stage of the Company’s
    scientific and business development growth,” said Dr. Benedyk. “I look forward to helping
    the Company as it advances MANF towards the clinic for Parkinson’s disease, and
    executes a commercial strategy for its promising clinical diagnostic tests for Parkinson’s
    and Alzheimer’s disease.”
    Gerald E. Commissiong, President and Chief Executive Officer of Amarantus BioScience,
    stated “Mark Benedyk has played a significant role in the growth and success of several
    leading healthcare companies. With his knowledge and understanding of clinical
    development and regulatory affairs, as well as the financial and operating requirements of
    a development-stage company, Mark will be an important resource for all aspects of
    managing our progress and creating value for shareholders.”
    Dr. Benedyk is currently a Managing Partner at Rila Partners LLC, a business and
    corporate development consultancy. In this role he serves on the Strategic Advisory Board
    of KemPharm, Inc., is a Director at the Center for Drug Research and Development
    Ventures, Inc., and is a member of the Translational Medicine Advisory Board of the CNS
    Regenerative Medicine Foundation. Previously he was head of The Pfizer Incubator (TPI)
    where his du

    Sentiment: Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
 
AMBS
0.0502-0.0013(-2.52%)Jun 1 3:59 PMEDT